Skip to main content
Premium Trial:

Request an Annual Quote

Invitae, PCT Therapeutics, Genome Medical Partner to Offer Genetic Testing for Cerebral Palsy

NEW YORK – PTC Therapeutics, Genome Medical, and Invitae are partnering to offer genetic testing free of charge to patients in the US who have symptoms or a diagnosis of cerebral palsy with no evidence of brain injury, PTC said on Wednesday.

The initiative, called PTC Pinpoint Direct-CP Spectrum, is a genetic testing program that includes genetic counseling for eligible patients. Genome Medical will provide the counseling and administration and Invitae the genetic testing. The partners are hoping that testing through PTC Pinpoint Direct-CP Spectrum may help uncover a genetic cause for each person's symptoms and determine the right plan for the patient's care, including new and emerging treatment options. PTC focuses on developing new therapies for patients with rare disorders.

The company noted that this is an extension of an existing program, PTC Pinpoint, and that it is designed to further eliminate barriers of genetic testing for rare diseases.

"An umbrella diagnosis of a neurotransmitter disorder, such as cerebral palsy, can be extremely frustrating, especially for patients and caregivers who spend years with unexplained and underlying symptoms," Kylie O'Keefe, senior VP of global commercial and corporate strategy for PTC, said in a statement. "Up to one-third of cerebral palsy cases are driven by a genetic disorder, and some of those conditions may have transformative treatments currently available."

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.